TECH - Bio-Techne Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Bio-Techne Corporation

614 McKinley Place NE
Minneapolis, MN 55413
United States

Full Time Employees2,255

Key Executives

NameTitlePayExercisedYear Born
Mr. Charles R. KummethCEO, Pres & Director2.56MN/A1960
Mr. James T. HippelSr. VP of Fin. & CFO968.88kN/A1971
Ms. Brenda S. FurlowSr. VP, Gen. Counsel, Sec. & Chief Compliance Officer643.23kN/A1958
Mr. N. David EansorPres of Protein Sciences Segment866.28kN/A1961
Mr. Gerry AndrosVP of Sales and MarketingN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers reagent solutions, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera reagents, and cell selection technologies. This segment also provides analytical solutions, including manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. In addition, it offers various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

Bio-Techne Corporation’s ISS Governance QualityScore as of July 29, 2019 is 1. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.